Clinical significance of CD200 expression in newly diagnosed multiple myeloma patients and dynamic changing during treatment

References

• Manier S, de Charette de la Contrie M, Hieulle J, et al. [Multiple myeloma: new criteria for diagnosis and treatment, strong therapeutic hopes]. Presse Med. 2019;48(7–8 Pt 1):825–831.
   PubMed Web of Science ®Google Scholar
• van Dongen JJ, Lhermitte L, Bottcher S, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012;26(9):1908–1975.
   PubMed Web of Science ®Google Scholar
• Flores-Montero J, Sanoja-Flores L, Paiva B, et al. Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017;31(10):2094–2103.
   PubMed Web of Science ®Google Scholar
• Olteanu H. Role of flow cytometry in the diagnosis and prognosis of plasma cell myeloma. Surg Pathol Clin. 2016;9(1):101–116.
   PubMedGoogle Scholar
• Barclay AN, Wright GJ, Brooke G, et al. CD200 and membrane protein interactions in the control of myeloid cells. Trends Immunol. 2002;23(6):285–290.
   PubMed Web of Science ®Google Scholar
• McWhirter JR, Kretz-Rommel A, Saven A, et al. Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation. Proc Natl Acad Sci USA. 2006;103(4):1041–1046.
   PubMed Web of Science ®Google Scholar
• Brunetti L, Di Noto R, Abate G, et al. CD200/OX2, a cell surface molecule with immuno-regulatory function, is consistently expressed on hairy cell leukaemia neoplastic cells. Br J Haematol. 2009;145(5):665–667.
   PubMed Web of Science ®Google Scholar
• D’Arena G, Valvano L, Vitale C, et al. CD200 and prognosis in chronic lymphocytic leukemia: conflicting results. Leuk Res. 2019;83:106169.
   PubMed Web of Science ®Google Scholar
• Sandes AF, de Lourdes Chauffaille M, Oliveira CR, et al. CD200 has an important role in the differential diagnosis of mature B-cell neoplasms by multiparameter flow cytometry. Cytometry B Clin Cytom. 2014;86(2):98–105.
   PubMed Web of Science ®Google Scholar
• Tiribelli M, Raspadori D, Geromin A, et al. High CD200 expression is associated with poor prognosis in cytogenetically normal acute myeloid leukemia, even in FlT3-ITD-/NPM1+ patients. Leuk Res. 2017;58:31–38.
   PubMed Web of Science ®Google Scholar
• D'Arena G, Vitale C, Rossi G, et al. CD200 included in a 4-marker modified Matutes score provides optimal sensitivity and specificity for the diagnosis of chronic lymphocytic leukaemia. Hematol Oncol. 2018;36(3):543–546.
   Web of Science ®Google Scholar
• D’Arena G, Vitale C, Coscia M, et al. External validation of the accuracy of ‘CLLflow score’. J Investig Med. 2018;66(7):e6.
   PubMed Web of Science ®Google Scholar
• Alapat D, Coviello-Malle J, Owens R, et al. Diagnostic usefulness and prognostic impact of CD200 expression in lymphoid malignancies and plasma cell myeloma. Am J Clin Pathol. 2012;137(1):93–100.
   PubMed Web of Science ®Google Scholar
• Aref S, Azmy E, El-Gilany AH. Upregulation of CD200 is associated with regulatory T cell expansion and disease progression in multiple myeloma. Hematol Oncol. 2017;35(1):51–57.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-548–e548.
   Web of Science ®Google Scholar
• Arroz M, Came N, Lin P, et al. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting. Cytometry B Clin Cytom. 2016;90(1):31–39.
   PubMed Web of Science ®Google Scholar
• Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–e346.
   PubMed Web of Science ®Google Scholar
• Olteanu H, Harrington AM, Hari P, et al. CD200 expression in plasma cell myeloma. Br J Haematol. 2011;153(3):408–411.
   PubMed Web of Science ®Google Scholar
• Tazawa S, Shiozawa E, Homma M, et al. CD200 expression on plasma cell myeloma cells is associated with the efficacies of bortezomib, lenalidomide and thalidomide. J Clin Exp Hematop. 2015;55(3):121–126.
   PubMed Web of Science ®Google Scholar
• Moreaux J, Hose D, Reme T, et al. CD200 is a new prognostic factor in multiple myeloma. Blood. 2006;108(13):4194–4197.
   PubMed Web of Science ®Google Scholar
• Aref S, Azmy E, El-Gilany AH. Upregulation of CD200 is associated with regulatory T cell expansion and disease progression in multiple myeloma. Hematolog Oncol. 2017;35(1):51–57.
   PubMed Web of Science ®Google Scholar
• Douds JJ, Long DJ, Kim AS, et al. Diagnostic and prognostic significance of CD200 expression and its stability in plasma cell myeloma. J Clin Pathol. 2014;67(9):792–796.
   PubMed Web of Science ®Google Scholar
• Gorczynski RM, Zhu F. Checkpoint blockade in solid tumors and B-cell malignancies, with special consideration of the role of CD200. Cancer Manag Res. 2017;9:601–609.
   PubMed Web of Science ®Google Scholar
• Gorczynski RM, Chen Z, Yu K, et al. CD200 immunoadhesin suppresses collagen-induced arthritis in mice. Clin Immunol. 2001;101(3):328–334.
   PubMed Web of Science ®Google Scholar
• Koike M, Sekigawa I, Okada M, et al. Relationship between CD4(+)/CD8(+) T cell ratio and T cell activation in multiple myeloma: reference to IL-16. Leuk Res. 2002;26(8):705–711.
   PubMed Web of Science ®Google Scholar
• Massaia M, Dianzani U, Bianchi A, et al. Defective generation of alloreactive cytotoxic T lymphocytes (CTL) in human monoclonal gammopathies. Clin Exp Immunol. 1988;73(2):214–218.
   PubMed Web of Science ®Google Scholar
• Willenbacher W, Willenbacher E, Zelle-Rieser C, et al. Bone marrow microenvironmental CD4 + and CD8 + lymphocyte infiltration patterns define overall- and progression free survival in standard risk multiple myeloma-an analysis from the Austrian Myeloma Registry. Leuk Lymphoma. 2016;57(6):1478–1481.
   PubMed Web of Science ®Google Scholar
• Gu Y, Jin Y, Ding J, et al. Low absolute CD4(+) T cell counts in peripheral blood predict poor prognosis in patients with newly diagnosed multiple myeloma. Leuk Lymphoma. 2020;61(8):1869–1876.
   PubMed Web of Science ®Google Scholar
• Gorczynski RM. CD200 and its receptors as targets for immunoregulation. Curr Opin Investig Drugs. 2005;6(5):483–488.
   PubMedGoogle Scholar
• Mahadevan D, Lanasa MC, Farber C, et al. Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200. J Immunother Cancer. 2019;7(1):227.
   PubMed Web of Science ®Google Scholar